Proteasome inhibitors (PIs) are a fascinating class of small molecules that disrupt protein
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …

Multiple myeloma (MM) cell lines are routinely used to model the disease. However, a long-
standing question is how well these cell lines truly represent tumor cells in patients. Here …

Purpose Few targeted treatment options currently exist for patients with advanced, often
recurrent breast cancers, both triple-negative breast cancer (TNBC) and hormone receptor …

Proteasomes are multi-subunit complexes that specialize in protein degradation. Cancer
cells exhibit a heightened dependence on proteasome activity, presumably to support their …

Proteasome inhibitor (PI) resistance remains a central challenge in multiple myeloma. To
identify pathways mediating resistance, we first mapped proteasome-associated genetic co …

Infections are common in plasma cell cancer multiple myeloma (MM) due to disease-related
immune deficiencies and cancer treatment. Myeloma cells express Toll-like receptors …

The neurotoxic effects of the chemotherapeutic agent bortezomib on dorsal root ganglia
sensory neurons are well documented, yet the mechanistic underpinnings that govern these …

Much remains to be determined about the participation of ubiquitin receptors in proteasomal
degradation and their potential as therapeutic targets. Suppression of the ubiquitin receptor …

Proteasome inhibitor (PI) resistance remains a central challenge in multiple myeloma. To
identify pathways mediating resistance, we first map proteasome-associated genetic co …

Potential New Therapies for Sarcomas: Testing the Efficacy of proteasome inhibitors
Bortezomib and Ixazomib against Ewing Sarcom Page 1 1 Potential New Therapies for …